CCR5 and COVID-19: Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, is well tolerated without significant side effects in its current use in patients with HIV; in patients with COVID-19, it has been used as a drug against the main protease (Mpro) of SARS-CoV-2 (determined by computer methods) [30].